Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04749407

Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer

Non-small Cell Lung Cancer Stage III Clinical Trial

Official title:
Dynamic Biomarkers of Immune Microenvironment for Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer

Clinical Trial Summary

This study aims to dynamically monitor the expression profile status of peripheral blood mononuclear cells (PBMC) and the changes in circulating tumor DNA (ctDNA) levels in patients with stage III locally advanced unresectable non-small-cell lung cancer(NSCLC) after concurrent chemoradiotherapy or sequential chemoradiotherapy, and to explore biomarkers related to the immune microenvironment and the optimal time point for immunotherapy after chemoradiotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04749407
Study type Observational
Source First People's Hospital of Hangzhou
Contact Shirong Zhang, Ph.D
Phone 057156007664
Email shirley4444@gmail.com
Status Not yet recruiting
Phase
Start date February 2021
Completion date December 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05557552 - Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly and/or Frail Stage III Non-small-cell Lung Cancer N/A
Active, not recruiting NCT04765709 - Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC Phase 2
Not yet recruiting NCT06449313 - Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advance Non-Small Cell Lung Cancer Phase 2
Not yet recruiting NCT06031597 - Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy Phase 3
Recruiting NCT04728724 - Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer Phase 2
Not yet recruiting NCT05451173 - Combining ICI With SBRT or HypoFrx-RT for ES NSCLC Phase 1/Phase 2
Completed NCT06015815 - The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT
Completed NCT03728556 - A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer Phase 3
Recruiting NCT04586465 - Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC Phase 2
Not yet recruiting NCT05548504 - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC Phase 2
Completed NCT02434081 - NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma Phase 2
Not yet recruiting NCT02946216 - ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC N/A
Completed NCT03550482 - Oncoxin® and Quality of Life in Cancer Patients Phase 4
Recruiting NCT05398094 - Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy Phase 2
Completed NCT02418234 - T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure N/A
Recruiting NCT05338619 - A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy Phase 2
Not yet recruiting NCT05414630 - A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer Phase 2
Withdrawn NCT04941365 - Quantifying Systemic Immunosuppression to Personalize Cancer Therapy N/A
Not yet recruiting NCT06463665 - Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25) Phase 2
Active, not recruiting NCT04699721 - Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC Phase 1